This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chène, P. Search for Related Content PubMed PubMed Citation Articles by Chène, P. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

---

Subject Review

Inhibition of the p53-MDM2 Interaction: Targeting a Protein-Protein Interface

Oncology Department, Novartis, Basel, Switzerland

Requests for reprints: Patrick Chène, Oncology Department, Novartis, K125 443, CH-4002 Basel, Switzerland. Phone: 41-61-696-2050; Fax: 41-61-696-3835. E-mail: patrick_chene{at}yahoo.com

MDM2 inhibits p53 transcriptional activity, favors its nuclear export, and stimulates its degradation. Inhibition of the p53-MDM2 interaction with synthetic molecules should therefore lead to both the nuclear accumulation and the activation of p53 followed by the death of the tumor cells from apoptosis. Inhibitors of the p53-MDM2 interaction might be attractive new anticancer agents that could be used to activate wild-type p53 in tumors. This review describes our current knowledge on the properties of the existing p53-MDM2 antagonists. Because the discovery of modulators of protein-protein interactions is an emerging field in drug discovery, the strategy used for designing inhibitors of the p53-MDM2 interaction could serve as an example for other protein interfaces.

This article has been cited by other articles:

				A. Forslund, Z. Zeng, L.-X. Qin, S. Rosenberg, M. Ndubuisi, H. Pincas, W. Gerald, D. A. Notterman, F. Barany, and P. B. Paty MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers Mol. Cancer Res., February 1, 2008; 6(2): 205 - 211. [Abstract] [Full Text] [PDF]

				J. R. Elison, D. Cobrinik, N. Claros, D. H. Abramson, and T. C. Lee Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells. Arch Ophthalmol, September 1, 2006; 124(9): 1269 - 1275. [Abstract] [Full Text] [PDF]

				M.-S. Dai, D. Shi, Y. Jin, X.-X. Sun, Y. Zhang, S. R. Grossman, and H. Lu Regulation of the MDM2-p53 Pathway by Ribosomal Protein L11 Involves a Post-ubiquitination Mechanism J. Biol. Chem., August 25, 2006; 281(34): 24304 - 24313. [Abstract] [Full Text] [PDF]

				Y. Tabakin-Fix, I. Azran, Y. Schavinky-Khrapunsky, O. Levy, and M. Aboud Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications Carcinogenesis, April 1, 2006; 27(4): 673 - 681. [Abstract] [Full Text] [PDF]

				N. C. Arva, T. R. Gopen, K. E. Talbott, L. E. Campbell, A. Chicas, D. E. White, G. L. Bond, A. J. Levine, and J. Bargonetti A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells J. Biol. Chem., July 22, 2005; 280(29): 26776 - 26787. [Abstract] [Full Text] [PDF]

				K. G. McLure, M. Takagi, and M. B. Kastan NAD+ Modulates p53 DNA Binding Specificity and Function Mol. Cell. Biol., November 15, 2004; 24(22): 9958 - 9967. [Abstract] [Full Text] [PDF]